ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca will open its compound library to Medicines for Malaria Venture, a nonprofit group working to speed the development of new malaria treatments. MMV has enlisted Vicky Avery of Australia’s Griffith University to screen the library’s 500,000 compounds against Plasmodium falciparum, the most lethal of the malaria parasites. Any promising compounds will be funneled to AstraZeneca’s R&D facility in Bangalore, India, for further exploration. AstraZeneca appears to be upping its commitment to neglected diseases: This spring, the firm teamed with the Global Alliance for TB Drug Development to create a joint portfolio of compounds active against tuberculosis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter